The 2002 Study That Changed Everything, and Was Wrong
The Women's Health Initiative (WHI) study, published in 2002, appeared to show that combined HRT increased breast cancer and cardiovascular risk. The media response was immediate and catastrophic: millions of women stopped HRT overnight. HRT prescriptions in the US fell by 70% within a year. What was not widely reported: the WHI studied older women (average age 63) given oral conjugated equine oestrogen combined with medroxyprogesterone acetate, a synthetic progestin. These are not the preparations used today.
What the Updated Evidence Shows
Re-analysis of WHI data and subsequent large prospective studies have substantially revised the risk picture. For women who start HRT within 10 years of menopause (the "window of opportunity") or before age 60, the benefits, symptom relief, cardiovascular protection, bone density preservation, and potential cognitive benefits, outweigh the risks for most women. Modern transdermal (skin patch or gel) oestrogen does not carry the VTE (blood clot) risk of oral oestrogen. Micronised progesterone (body-identical) appears safer than synthetic progestins regarding breast tissue.
The Real Breast Cancer Risk in Context
For combined HRT, any increased breast cancer risk is broadly comparable to the increased risk associated with drinking two units of alcohol per night or being overweight. It is a real risk that should inform individual decision-making, but it is not the catastrophic risk that was communicated in 2002, and it should not be the only consideration. For oestrogen-only HRT in women without a uterus, the data is even more reassuring.
Having the Conversation With Your Doctor
Every woman deserves an individualised risk-benefit discussion. Your personal medical history, family history, symptom severity, and preferences should all be part of the decision. If your GP is still advising against HRT based on 2002 data, ask for a referral to a menopause specialist. The British Menopause Society and NICE guidelines (UK) both strongly support HRT as first-line treatment for menopausal symptoms in appropriate candidates.
Medical Disclaimer
This article is written for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.
Dr. Lisa Park
MD, FACOG
All TryHerCare articles are written and reviewed by qualified medical professionals. Our content is clinician-reviewed to ensure accuracy and clinical relevance.
